BIOMAT Database Logo BIOMAT Database Logo

Massive mediastinal involvement in stage I-II Hodgkin's disease: response to combined modality treatment. 1992

P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Institute of Hematology L. e A. Seràgnoli, University of Bologna, Italy.

Thirty-seven patients with stage I-II Hodgkin's disease and massive mediastinal involvement, observed between June 1981 and November 1989, underwent combined modality treatment. This treatment included: 3 cycles of mechlorethamine, vincristine, procarbazine, and prednisone followed by mantle-field irradiation, and subsequently by 3 additional cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Thirty-five (95%) patients achieved complete responses and only 2 (5%) had partial responses. All the complete responders are living and relapse-free at a median follow-up of 62 months; no major toxic reactions were recorded. These data suggest, as did those of other studies, that combined modality therapy is superior to either radiotherapy or chemotherapy alone for patients in stage I-II with bulky disease, especially in the mediastinum. In fact, in these particular patients, if adequately treated with a combination of chemotherapy and radiotherapy, the role of massive mediastinal involvement as a poor prognostic factor appears to be less significant.

UI MeSH Term Description Entries
D008297 Male Males
D008482 Mediastinum A membrane in the midline of the THORAX of mammals. It separates the lungs between the STERNUM in front and the VERTEBRAL COLUMN behind. It also surrounds the HEART, TRACHEA, ESOPHAGUS, THYMUS, and LYMPH NODES.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
February 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease.
April 1982, Cancer treatment reports,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Combined modality treatment in stage I and II diffuse non-Hodgkin's lymphomas.
January 1985, Progress in clinical and biological research,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
[Treatment of local Hodgkin's disease with massive mediastinal involvement].
January 2000, Terapevticheskii arkhiv,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse.
August 1980, European journal of cancer,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy.
April 1993, International journal of radiation oncology, biology, physics,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Mediastinal Hodgkin's disease. Significance of mediastinal involvement in early stage Hodgkin's disease.
January 1984, Hematological oncology,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.
July 1996, Seminars in radiation oncology,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy.
July 1988, International journal of radiation oncology, biology, physics,
P L Zinzani, and P Mazza, and F Gherlinzoni, and M Bocchia, and M Fiacchini, and M Bendandi, and E Barbieri, and G Frezza, and S Neri, and E Aitini
Mediastinal irradiation in combined modality therapy for Hodgkin's disease.
September 1990, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!